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Abstract
Therapeutic proteins such as monoclonal antibodies, replacement enzymes and toxins have significantly improved the
therapeutic options for multiple diseases, including cancer and inflammatory diseases as well as enzyme deficiencies and
inborn errors of metabolism. However, immune responses to these products are frequent and can seriously impact their
safety and efficacy. Of the many factors that can impact protein immunogenicity, this study focuses on the role of innate
immune response modulating impurities (IIRMIs) that could be present despite product purification and whether these
impurities can synergize to facilitate an immunogenic response to therapeutic proteins. Using lipopolysaccharide (LPS) and
CpG ODN as IIRMIs we showed that trace levels of these impurities synergized to induce IgM, IFNc, TNFa and IL-6
expression. In vivo, trace levels of these impurities synergized to increase antigen-specific IgG antibodies to ovalbumin.
Further, whereas mice treated with human erythropoietin showed a transient increase in hematocrit, those that received
human erythropoietin containing low levels of IIRMIs had reduced response to erythropoietin after the 1
st dose and
developed long-lasting anemia following subsequent doses. This suggests that the presence of IIRMIs facilitated a breach in
tolerance to the endogenous mouse erythropoietin. Overall, these studies indicate that the risk of enhancing
immunogenicity should be considered when establishing acceptance limits of IIRMIs for therapeutic proteins.
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Introduction
Biotechnology products, in many cases recombinant proteins,
are derived from complex expression/production systems that
often involve genetically modified host cells (bacteria, yeast, insect
or mammalian) and complex growth/fermentation media [1]. The
ensuing purification steps may be insufficient to completely
eliminate impurities such as DNA, host cell proteins, or endotoxins
from the product. As a result, biologics may contain low levels of
host cell or process derived impurities [2]. These impurities, which
we designate as Innate Immune Response Modifying Impurities
(IIRMIs), can potentially stimulate the innate immune system via a
host of pattern recognition receptors and foster the development of
an immune response to the product. Immune responses to protein
therapeutic products, including the production of anti-drug
antibodies or cell-based immune responses, are frequent [3,4].
While some immune responses do not appear to have clinical
implications, others result in infusion reactions (e.g. hypersensitiv-
ity), alter the drug’s pharmacokinetics, neutralize or otherwise
compromise the clinical safety or efficacy of a product [1,5]. Such
is the case for patients who receive replacement therapies for
hemophilia or inborn errors of metabolism such as Pompe’s
disease, where the development of neutralizing antibodies to the
replacement therapy deprives the patients from a life saving
therapy [6–8]. In addition, immune responses to therapeutic
proteins can result in loss of tolerance to their endogenous
counterparts leading to serious adverse events [1]. Examples of
these include the development of pure red cell aplasia in patients
treated with EprexH [9], and of thrombocytopenia in patients that
received as few as 2 doses of a truncated and pegylated
recombinant thrombopoietin [10].
Immune cells express numerous receptors that respond to
conserved microbial molecular patterns [11–13]. The family of
Toll like receptors (TLR) recognizes distinct highly conserved
microbial components. For example, TLR 4 recognizes lipopoly-
saccharide (LPS), TLR 9 is activated by DNA encoding
unmethylated cytosine-phosphate guanine motifs (CpG motifs),
and TLR 3 responds to double-stranded RNA [14]. Multiple
studies show that ligands for these TLR can be used to increase the
immunogenicity of foreign proteins [15] and may facilitate the
breaking of tolerance to self [16]. Indeed, data from the field of
vaccine adjuvants shows that in mice, addition of 25–100 mgo f
CpG ODN or 10–100 mg of LPS to a protein antigen potentiates
the production of antigen-specific antibodies, T cell survival and
Th1 differentiation to the protein [17–20]. Several studies have
further shown that low levels of peptidoglycans or TLR 7 agonists
can synergize with TLR 3 or TLR 4 agonists to foster secretion of
IL-12 and other cytokines by dendritic cells (DC) [21–25] and
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there are no formal studies addressing the impact of combinations
of very low level TLR agonists on the immunogenicity of
therapeutic proteins.
In this study we hypothesized that TLR-stimulating impurities,
at levels close to the limit of detection by currently used analytical
methods, may stimulate the immune system and impact the
product in terms of its immunogenicity, particularly when more
than one type of impurity is present. Using LPS and synthetic
DNA strands containing CpG motifs as a model we determined
that trace levels of TLR 4 and 9 agonists synergize to induce
cellular activation with increased cytokine and chemokine
expression and antibody production both in vitro and in vivo.
Materials and Methods
Reagents and media
Phosphorothioate CpG ODN (GCTAGACGTTAGCGT) and
Control ODN (GCTAGAGCTTAGGCT) were synthesized at
the CBER core facility. All ODN had less than ,0.1 EU of LPS
per mg of ODN as assessed by a Limulus amebocyte lysate assay
(QCL-1000, BioWhittaker, Walkersville, MD). E. coli LPS
(0111:B4) were purchased from InvivoGen (San Diego, CA) and
used per manufacturer’s instructions. The stated potency of the
endotoxin is 1EU/ng. Ultrapure Ovalbumin (Ovalbumin grade V,
OVA) was obtained from Sigma-Aldrich. Ovalbumin used to
immunize mice was a kind gift from Brian Kelsall (NIAID, NIH)
and contained less than 0.025EU of endotoxin per 5 mg OVA as
assessed by the LAL assay. Human Erythropoietin (rhuEPO) was
purchased from GenScript Corporation (Piscataway, NJ). Endo-
toxin content in rhuEPO was measured using LAL Assay as above.
Mice and experimental design
Animal studies were conducted under protocol 2006-43 as
approved by the White Oak Animal care and Use Committee of
the FDA. Mice used for study were obtained from the National
Cancer Institute (Frederick, MD). In one study, 2 month old
female BALB/c mice (n=5/group) were immunized with 5 mgo f
OVA alone or together with different amounts of CpG ODN or
LPS as specified for each experiment. The animals were boosted 3
weeks later with the same preparation. Mice that received saline
were used as controls. Mice were tail-bled before the immuniza-
tion and weekly thereafter. For another study, two month old
female C57BL/6 mice (n=5/group) received 5 mg of rhuEPO
alone or together with the TLR agonists (i.p.). Mice that received
saline served as controls to establish the natural variability of the
hematocrit and the impact of serial tail bleeding. After first dose,
blood was collected and HCT was measured weekly/biweekly.
Animals were re-treated 14 and 62 days after first injection.
Percent of increased/reduced hematocrit was calculated relative to
the baseline for each individual mouse.
Quantitative Real-Time PCR (q-RT-PCR)
Total RNA was prepared from splenocytes using TRIzol
(Invitrogen, Paisley, Scotland, UK) as per manufacturer instruc-
tions and then purified with RNAeasy (Qiagen, Valencia, CA).
Subsequently, RNA (500 ng/sample) was reverse transcribed into
cDNA using a High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems Inc., Foster City, CA, USA) as per
manufacturer’s instructions. cDNA samples were treated RNase
H (Invitrogen) for 30 minutes at 37uC and stored at 220uC until
used for q-RT-PCR. Expression values were calculated using the
2
2DDCt method [27]. For the mRNA array, total RNA was then
reverse transcribed and subsequently analyzed on TaqMan Low
Density Array cards by TaqMan PCR using a 7900HT (ABI) as
per manufacturer’s instruction.
Cytokine and Antibody Assays
Supernatants: 5610
5 splenocytes/well were cultured in RPMI
10% FCS media at 37uC for 48 hr. IFNc, IL-6, and Ig were
assessed by using 96-well plates (Immunolon, Thermo LabSys-
tems, Franklin MA) coated with cytokine-specific antibody or
antigen and then blocked with PBS-1% bovine serum albumin
(Sigma, St Louis, MO). After washing, the plates were overlaid
with the supernatant for 3 hours, then further washed, and treated
with the appropriate biotinylated secondary antibody, followed by
AKP-conjugated avidin (BD, Biosciences, Franklin Lakes, NJ).
Absorbance was read at 405nm.
Statistical analysis
Changes in antibody or cytokine expression were analyzed by t
test, ANOVA or repeated measure ANOVA as appropriate.
Differences in hematocrit were evaluated by SAS using a mixed
model with repeated measures where HCT=treat+day+treat*
day+treat*day
2+treat*day
3. P values,0.05 were considered
significant.
Results
Substimulatory levels of LPS and CpG ODN synergize to
induce an immune response
Endotoxin and host cell DNA are impurities routinely
monitored in the manufacture of biologics. Both can stimulate
the innate immune system via the TLR system and function as
adjuvants enhancing the immunogenicity of proteins by activating
antigen presenting cells, inducing cytokine secretion and directing
polyclonal B cell activation [11]. In vitro, optimal stimulation of
splenocytes can be achieved using 10 mg/ml LPS or 1–3 mM (4–
12 mg/ml) CpG ODN. However, as shown in figure 1, concen-
trations of LPS as low as 10 ng/ml (10 EU/ml) consistently
stimulated increased mRNA and protein expression for IL-6 and
IFNc in Balb/c splenocytes, while 20–50 nM (0.02–0.05mg/ml) of
synthetic DNA encoding a CpG motif were sufficient to induce
these cytokines in vitro. Splenocytes from C57Bl/6 mice exhibited
similar results (data not shown). These trace levels of TLR 4 and 9
agonists also elicited B cells activation as evidenced by an increase
in total IgM and IgG output and upregulation of MHC class II
and CD86 expression (fig 1c&d).
To assess whether the presence of low levels of both IIRMIs
together would further increase immune activation, splenocytes
were stimulated with the lowest levels of LPS (10ng/ml) and CpG
ODN (20 nM) that induced a reproducible response in vitro. The
breadth of the activation was determined using TaqMan low
density DNA arrays (TLDA) for 92 immune-related genes
(supplementary Table S1). As shown in figure 2, the addition of
both stimuli together triggered a significant increase in mRNA for
TBx21, IFNc and IFNc- inducible proteins, CXCL10 and
CXCL11, as well as interleukin 6 (IL-6), granzyme B, nitric oxide
synthase 2 (nos2) and cycloxygenase 2 (cox2) suggesting that the
presence of these IIRMIs fosters a pro-inflammatory/type I
response. In contrast, while individually LPS and CpG ODN
induced small increases in IL-4, IL-5 and IL-10 mRNA
expression, no synergy was evident. The increased mRNA
expression was sustained for at least 24 hours and resulted in
dose-dependent increases in IFNc and IL-6 protein concentration
in culture supernatants, as shown in figure 3a. In the presence of
sub-stimulatory levels of CpG ODN (12.5 nM), concentrations of
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IL-6 production.
Submitogenic levels of LPS and CpG ODN synergize to
enhance antibody responses to proteins. In B cells, TLR
activation results in the up-regulation of activation markers,
proliferation, cytokine secretion, terminal differentiation into
plasma cells and, finally, immunoglobulin secretion [28–32].
When used as adjuvants, TLR agonists were shown to augment B
cell responses to specific protein antigens even in the absence of
capable T cell help [33]. To establish whether the presence of
substimulatory levels of LPS and CpG DNA would promote
polyclonal B cell activation, splenocytes were stimulated with low
levels of LPS and CpG DNA as described above. As shown in
figure 4, TLR agonists synergized to increase the secretion of total
IgM (figure 4a) and the expression of CD86, CD69 and MHC II
on B cells (figure 4b).
Protein immunogenicity in vivo. Numerous studies have
demonstrated that TLR 4 and TLR 9 agonists in optimal amounts
(10–100 mg for LPS and 25–100 mg for CpG ODN) significantly
increased the efficacy of vaccines in murine models [17,34–36]. To
determine whether trace amounts of TLR agonists were sufficient
to increase the immunogenicity of a foreign protein in rodents,
Balb/c mice were immunized with LPS-free ovalbumin (5 mg/
mouse, subcutaneously) alone or together with LPS (10 ng–1mg/
animal) or CpG ODN (500 ng–5mg/animal) individually, or the
combination. As shown in figure 5, administration of ovalbumin
alone or together with trace or suboptimal amounts of a single
TLR-agonist induced very low levels of IgG antibodies. In
contrast, mice that received the same dose of ovalbumin
together with 10 ng of LPS plus 500 ng of CpG ODN had
significantly increased (p,0.05) IgG antibody responses to
ovalbumin 3 weeks post treatment. The same group showed
significantly higher antibody titers following re-exposure 4 weeks
after priming (p,0.005). Indeed, the antibody levels in these mice
were significantly higher than those immunized with ovalbumin
together with either 5 mg of CpG ODN or 1 mg of LPS (p,0.05).
TLR-binding impurities can synergize to break tolerance
to endogenous proteins. Tolerance to low-abundance self
proteins in sera is incomplete and may be overcome when these
proteinsarepresented inthe context ofadequate adjuvants[37–39].
Using a model established by Ryan et al. [40], we determined
whether the addition of low levels of LPS and/or CpG DNA was
sufficient to induce a breach in tolerance and the induction of a
neutralizing response to erythropoietin. Balb/c mice were treated
Figure 1. Induction of IL-6 and IFNc by increasing concentrations of LPS and CpG ODN. Balb/c splenocytes (2610
6/ml; n=2–5) were
placed in culture with increasing concentrations of LPS or CpG ODN. a. Fold increase in mRNA relative to unstimulated cells from the same animal
were determined by q-RT-PCR after 12 hours. b/c. IFNc and IL-6 and total immunoglobulin levels in 48 hr supernatants as determined by ELISA. d.
shows the expression of MHC-II and CD86 in CD19
+-CD220
+ B cells 48 hours after stimulation in vitro. Shown is 1 of 3 experiments with similar results.
The dose dependent increase in mRNA and protein expression was tested by repeated measures ANOVA and regression analysis.
doi:10.1371/journal.pone.0015252.g001
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together with low levels of LPS and/or CpG ODN on days 0, 14
and 62, followed by weekly hematocrit measurements. As shown in
figure 6, the hematocrit of untreated mice remains constant over
time (5163%). Despite having only 80% homology with mouse
[41], rhuEPOwasactiveinmice,elicitinga reproducible increasein
the hematocrit 1 week after each treatment (15.5, 13.9 and 13.6%
increase over baseline after the 1
st,2
nd and 3
rd dose respectively).
Addition of low levels of CpG ODN (50 or 500 ng), LPS (100 pg) or
the combination (50 ng CpG ODN +100pg LPS) did not modify
the response. In mice treated with rhuEPO together with LPS
(10ng) there was evidence of reduced hematocrit following the 2
nd
inoculation. In contrast, mice treated with rhuEPO in combination
with 500 ng of CpG ODN plus 10 ng of LPS showed reduced
response to rhuEPO following one treatment as evidenced by
increases in hematocrit of 23, 7 and 1.5% over baseline after the 1
st,
2
nd and 3
rd inoculations respectively, followed by a pronounced
reduction in hematocrit (2%, 27% and 28% respectively relative to
baseline; p,0.001). The reduction in the hematocrit lasted for over
30 days following the 2
nd inoculation. This data shows that the
rhuEPO augments the hematocrit of mice for about 7 days. The
prolonged anemia observed in mice treated with rhuEPO plus LPS
and CpG ODN suggests that the inoculations led to a break in
tolerance to the endogenous (mouse) EPO, which is needed to
maintain the hematocrit stable. Together these data suggests that in
mice, the presence of low levels of impurities that can trigger TLR 4
and 9 are may foster a break in tolerance to an essential endogenous
non-redundant growth factor.
Discussion
In the vaccine field, the concept of immunostimulatory
combinations is being actively explored and studies using
combinations of TLR and NLR agonists have shown promise in
efforts to overcome tolerance to tumor antigens [42]. In
therapeutic proteins, where immune responses are not desired,
factors that can contribute to product immunogenicity such as the
degree of pre-existing tolerance, post-translation modifications,
glycosylation patterns, and the presence of aggregates are carefully
monitored [3]. The data above shows that process-related
impurities, especially those of microbial origin, may also play a
key role in the immunogenicity of therapeutic proteins. The effect
of IIRMIs was dose dependent and synergistic as levels of CpG
ODN and LPS that individually induced no or very low levels of
cytokine release by murine splenocytes, elicited polyclonal B cell
activation with increased antigen-specific immunoglobulin and
pro-inflammatory/Th1 cytokine output as well as up-regulation of
co-stimulatory molecules on the cell surface of antigen presenting
Figure 2. Suboptimal levels of LPS and CpG ODN synergize to induce the expression of IFN-related and proinflammatory genes in
splenocytes. Balb/c Splenocytes were placed in culture in the presence of low levels of LPS (10ng/ml) and/or CpG ODN (20nM). The breadth of
mRNA expression was determined using TaqMan low density DNA arrays (TLDA). A complete list of genes is available in supplemental Table S1.
Genes identified in the graph showed a significant increase in gene expression (p,0.05) and a mean fold increase .5 relative to unstimulated cells.
Differences in gene expression were assessed by ANOVA.
doi:10.1371/journal.pone.0015252.g002
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confirmed in vivo, as studies showed that the combination of 10 ng
of LPS and 500 ng of CpG ODN, which do not induce an
immune response when present individually, were sufficient to
promote the immunogenicity of proteins and contribute to a
clinically relevant break in tolerance to self.
Of note, this study was not designed to establish the minimal
concentration of TLR -binding impurities that could render a
protein immunogenic in humans, but to explore the potential for
increased protein immunogenicity when trace levels of multiple
impurities are present in a product. The minimal amount of TLR
4 and 9 agonists that can synergize to act as adjuvants in mice can
Figure 3. IFNc and IL-6 expression in cells stimulated with trace levels of LPS and CpG ODN. Splenocytes were cultured in the presence of
increasing concentrations of LPS and CpG ODN alone or in combination. a. The expression of mRNA was monitored for 24 hr and is shown as fold-
increase over time 0. b. Protein expression in culture supernatants was determined at 48 hr. LPS concentrations are expressed in ng/ml. Statistical
significance (* p,0.05; ***p,0.001): differences between treatment groups are noted as horizontal stars signal significant increase relative to the
corresponding concentration of CpG ODN, or as vertical stars, which show significant increase of dual stimulation over the corresponding
concentration of each individual stimulant (CpG ODN or LPS) (ANOVA, p,0.001).
doi:10.1371/journal.pone.0015252.g003
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concentrations of LPS and CpG ODN alone or in combination. a. Total IgM expression in culture supernatants was determined at 48 h by ELISA. LPS
concentrations are expressed in ng/ml. Statistical analysis: Repeated measure ANOVA*p,0.05, ***p,0.001.b. Cell surface expression of MHC-II and
CD86 on CD220
+ B cells. Show is 1 of 3 experiments with similar results.
doi:10.1371/journal.pone.0015252.g004
Figure 5. Trace levels of IIRMIs increase protein immunogencity in vivo. Balb/c mice (3–6 week old; 5 mice/group) were immunized and
boosted i.p. with human ovalbumin alone (5mg/mouse) or mixed with the stated amounts of LPS and/or CpG ODN. Mice that received saline were
used as controls. Mice were tail-bled before the immunization and weekly thereafter. Antibodies (IgG) to ovalbumin assessed by ELISA. Statistical
analysis: ANOVA. *=p,0.05, ** p,0.005, NS: Not significant.
doi:10.1371/journal.pone.0015252.g005
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increase protein immunogenicity in Man as i. animal models do
not predict immunogenicity in humans [1]; ii. mice and humans
differ significantly in their TLR distribution and sensitivity to
agonists [43]; and iii, humans are likely to be much more sensitive
to TLR agonists than rodents [44]. This is shown in studies using
CpG ODN as vaccine adjuvants, where 25–100 mg of CpG ODN
are used in mice weighing ,25–30 g compared to 100 mg–1mg of
CpG ODN in adult humans.
During the manufacture of therapeutic proteins a few IIRMIs,
such as LPS and DNA, are regularly screened-for and have
assigned limits or acceptance criteria for product release. Of note,
the current guidelines for setting limits on these impurities are not
based on their potential impact on product immunogenicity. For
example, the current recommendation for endotoxin content in
parenteral products (0.5 EU/kg/hr) is based on its pyrogenic
potential, while the WHO recommendations for DNA content
(,10 ng DNA/dose) are based on minimizing the risk of DNA
integration (USP ,85. and [45]). Yet studies using individual
TLR 4 or TLR 9 agonists as adjuvants show that concentrations
lower than those that may be pyrogenic or lead to significant DNA
integration can augment the immune response to co-administered
protein antigens [17,19,28]. Furthermore, as shown in the studies
above, the levels of agonists sufficient to stimulate an innate
response can be lower when multiple receptors are engaged.
Previous studies had shown that combinations of TLR and/or
NLR agonists in vitro increased the production of pro-inflamma-
tory cytokines such as IL-6, TNFa, IL-12 and type I IFNs by
macrophages and DC [21,46–48]. DC activated in this fashion
had prolonged expression of IkBj, sustained upregulation of
costimulatory molecules leading to the activation of polarized
antigen-specific CD4+ T cells, and reduced the regulatory effects
of CD4
+ CD25
+ Tregs on CD8
+ T cell responses in vitro
[21,48,49].
The precise mechanisms by which low levels of endotoxin and
DNA synergize to foster the activation of anergic B and T cells
specific for low-abundance self-antigens is still unknown at this
time. The synergy could result from enhanced activation and
cooperation among NF-kB, IRF, MAPK, PI-3K, and STAT
signaling pathways. TLR 9 is known to use Myeloid differentiation
primary response gene (88) (MyD88) while LPS can use both
MyD88 and TIR-domain-containing adapter-inducing interferon-
b (TRIF) as adaptor molecules. Of note, previous studies
cautioned that multiple stimuli that signal via the same
downstream pathway (such as MyD88 ) could result in a
dampened response to TLR agonists [50]. This led to hypothesize
Figure 6. Impurities can synergize to break tolerance to ‘‘self’’ proteins. Two month-old female C57BL/6 mice (n=5/group) received
rhuEPO (5 mg i.p. on day 0, 14 and 62) alone or together CpG ODN and/or LPS as shown (black arrows), and then bled (50 ml) every 7 or 14 days. Mice
that received saline served as controls. Results are expressed as the mean (6SD) hematocrit for each individual mouse (Mean 6 SEM). The gray box
shows the mean +3SD of the hematocrit of untreated mice over the time of the experiment. Those mice were bled with the same schedule as the
treated groups. Statistical analysis: SAS mixed model with repeated measures where HCT=treat+day+treat*day+treat*day
2+treat*day
3.
P values,0.05 were considered significant. * p,0.05; *** p,0.01.
doi:10.1371/journal.pone.0015252.g006
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MyD88 could synergize with those that used a different
transduction pathway such as TRIF [21]. Similar predictions
were made for IIRMs that signaled via Interferon regulatory factor
3 (IRF3) or IRF7 [21,51]. However, if the dampening effect of
multiple innate immune agonists is mediated by competition for
adaptor molecules, this restriction may not apply to trace level
impurities and therefore synergy may be evident regardless of
shared signaling paths. In addition, the enhancement could be
indirect as our preliminary studies show that TLR agonists can
upregulate other TLR receptors increasing the sensitivity to low
levels of ligand.
It is well established that the generation of immune responses to
therapeutic proteins can affect both the safety and efficacy of life-
saving products. Neutralizing antibody responses to therapeutic
proteins are particularly problematic when the endogenous
counterpart of the therapeutic protein serves a biologically unique
function. For instance, erythropoietin is a non-redundant growth
factor that stimulates and controls the development of erythroid
progenitors. It is present in human sera in very low levels (12–
15mU/ml) [52]. Between 1999 and 2002, following a manufac-
turing change, 206 patients treated with erythropoietin developed
pure red cell aplasia (PRCA) [53]. The increase in product
immunogenicity was attributed to a possible increase in leachables
from the container closure, but the precise factors that combined
to increase the immunogenicity in a small fraction of the patients
receiving treatment are still unresolved [54]. In our model, the
presence of very low levels of CpG ODN and LPS in rhuEPO was
sufficient to induce a clinically relevant reduction in hematocrit.
Previous studies have shown that administration of high levels of
CpG ODN (100 mg/mouse) can lead to a short term reduction in
hematocrit that was mediated by an increase in IFNc [55]. Our
study differs from Thawani et al’s in that the levels of CpG ODN
administered are 200 fold lower and do not induce per se a
reduction in the hematocrit. Further, in our model, the reduction
in hematocrit was more severe following a second or third
administration strongly suggesting that the reduction in hematocrit
was immune –and not inflammatory- mediated. Of note, the pro-
hematopietic effect of the rhuEPO in our mice lasted for about 1
week. In contrast, the hematocrit reduction following the
administration of rhuEPO plus LPS and CpG ODN lasted for
4–6 weeks. This suggests that anemia is the result of an immune
response that neutralized with activity of both the rhuEPO and the
mouse erythropoietin for an extended period. Together these data
suggest that the presence of trace levels of IIRMIs may facilitate an
immune response to a foreign protein and foster a break in
tolerance to a relatively homologous endogenous protein which
may cause a severe, albeit transient, deficiency syndrome.
In summary, our data suggests that levels of impurities
previously not known to contribute to product immunogenicity
may synergize to foster the response to a therapeutic protein.
These findings underscore the need to establish sensitive assays to
quantify the levels of any impurities that could activate the innate
immune system.
Supporting Information
Table S1 Trace levels of LPS and CpG ODN synergize to
induce mRNA expression of selected genes.
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